Patents Assigned to Shanghai Hengrui Pharmaceutical Co., Ltd.
  • Patent number: 10344034
    Abstract: Methods of preparation and pharmaceutical uses of pyrazolopyrimidone derivatives are described. Specifically, methods of preparation and pharmaceutical uses of pyrazolopyrimidone derivatives represented by the general formula (II) and pharmaceutically acceptable salts thereof are described, wherein the definitions of substituents in the general formula (II) are the same as the definitions in the specification. The pyrazolopyrimidone derivatives are useful as gonadotropin releasing hormone (GnRH) antagonists, such as for therapeutic agents for endometriosis.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: July 9, 2019
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Hejun Lu, Piaoyang Sun, Bin Gui, Qing Dong
  • Publication number: 20190070264
    Abstract: An interleukin 15 (IL-15) protein complex is provided. The IL-15 protein complex includes soluble fusion proteins (I) and (II), wherein the fusion protein (I) is an IL-15 polypeptide or a functional fragment thereof, and the soluble fusion protein (II) is an IL-15R? polypeptide or a functional fragment thereof. The soluble fusion protein (I) has at least one amino acid residue mutated to a cysteine (Cys) residue, which pairs with a corresponding mutated Cys residue on the soluble fusion protein (II), or vice versa, to form one or more disulfide bonds. The IL-15 protein complex can be used for tumor therapy.
    Type: Application
    Filed: November 17, 2015
    Publication date: March 7, 2019
    Applicants: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xiangdong QU, Xin YE, Qiyue HU, Dongbing CUI, Weikang TAO, Lianshan ZHANG, Piaoyang SUN
  • Patent number: 10206980
    Abstract: Provided is an IL-15 heterodimeric protein, such as an IL-15/IL-15R? heterodimeric protein. The IL-15 heterodimeric protein contains protein (I) and protein (II). Protein (I) is recombinantly produced by combining IL-15 or a variant thereof with a first Fc variant, and protein (II) is a second Fc variant, or recombinantly produced by combining IL-15R? or a variant thereof with a second Fc variant. The first Fc variant and the second Fc variant are preferably linked via a “Knob-into-Hole” mode. Also provided are methods of using the IL-15 heterodimeric proteins to modulate an immune response. The provided IL-15 heterodimeric proteins have significant anti-tumor activity, better biological activity and prolonged in vivo half-life compared to the IL-15 molecule alone.
    Type: Grant
    Filed: December 25, 2014
    Date of Patent: February 19, 2019
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Xiangdong Qu, Xin Ye, Jijun Yuan, Lei Zhang, Kan Chen, Lianshan Zhang, Guoqing Cao, Zhibin Xu, Weikang Tao
  • Publication number: 20180334504
    Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
    Type: Application
    Filed: November 2, 2016
    Publication date: November 22, 2018
    Applicants: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Xiangdong QU, Qiyue HU, Shaoyu XU, Dongbing CUI, Houcong JIN, Weikang TAO, Lianshan ZHANG, Guoqing CAO, Piaoyang SUN
  • Patent number: 10087191
    Abstract: The present invention relates to a piperidine derivative and the preparation method and a pharmaceutical use thereof. In particular, the present invention relates to the piperidine derivative as shown by general formula (I) and the preparation method thereof and a pharmaceutical composition containing the same, and the use thereof as an estrogen receptor modulator in the treatment of estrogen receptor mediated or dependent diseases or conditions, the diseases preferably being breast cancer. In the abstract, the definition of each substituent of the general formula (I) is the same as that in the description.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: October 2, 2018
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Shanghai Yu, Fanglong Yang, Lei Chen, Jingjing Yan, Xiqian Zhang, Zhichao Xie, Lingxiang Chen, Mingxun He
  • Patent number: 10081629
    Abstract: Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof are provided. Specifically, amide derivatives represented by general formula (I) are provided. The amide derivatives represented by general formula (I) can be used as a therapeutic agent, particularly as an inhibitor for microsomal prostaglandin E synthase-1 (mPGES-1), and also to treat and/or prevent diseases or illnesses such as inflammation and/or pain etc. The definition of each substituent group in general formula (I) is the same as the definition in the description.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: September 25, 2018
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xin Li, Wei He, Xianbo Liu, Bin Wang, Qiyue Hu, Fangfang Jin, Qing Dong, Piaoyang Sun
  • Patent number: 10064848
    Abstract: Compounds for the preparation of pyridone derivatives are provided. In particular, compounds of formula (IA) are provided, wherein the variable groups are as defined in the specification. The compounds of formula (IA) can be used as intermediates in the preparation of pyridone derivatives useful as mitogen-activated protein kinase kinase (MEK) inhibitors and therapeutic agents for treating cancer.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: September 4, 2018
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Wangyang Tu, Haitang Zhang, Guoji Xu, Jiangtao Chi
  • Patent number: 10022365
    Abstract: A liposome of irinotecan or irinotecan hydrochloride and its preparation method are disclosed. The liposome contains irinotecan or irinotecan hydrochloride, neutral phospholipid and cholesterol, wherein the weight ratio of the cholesterol to the neutral phospholipid is 1:3 to 1:5. The liposome is prepared by an ion gradient method.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: July 17, 2018
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xinyong Tong, Guofeng Lei, Chengxia Yu, Liang Chen
  • Patent number: 10005781
    Abstract: Pyrazolopyrimidone and pyrrolotriazone derivatives, methods of preparation thereof, and pharmaceutical uses thereof are described. Specifically, pyrazolopyrimidone and pyrrolotriazone derivatives represented by the general formula (I) and pharmaceutically acceptable salts thereof are described. The pyrazolopyrimidone and pyrrolotriazone derivatives are useful as gonadotropin releasing hormone (GnRH) antagonists, such as for therapeutic agents for endometriosis. The definitions of the substituents in the general formula (I) are the same as the definitions in the specification.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: June 26, 2018
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Hejun Lu, Piaoyang Sun, Bin Gui, Qing Dong
  • Publication number: 20180118750
    Abstract: The present invention relates to an imidazo isoindole derivative, a preparation method therefor and a medical use thereof. In particular, the present invention relates to the imidazo isoindole derivative as shown in the formula (I), a preparation method and pharmaceutical composition containing the derivative, and a use thereof for treating diseases with a pathological characteristic of the IDO-mediated tryptophan metabolic pathways. The diseases comprise cancers, Alzheimer's disease, autoimmune diseases, depression, anxiety disorders, cataracts, psychological disorders and AIDS, wherein the substituents in the formula (I) are the same as those defined in the specification.
    Type: Application
    Filed: April 12, 2016
    Publication date: May 3, 2018
    Applicants: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Wangyang TU, Guoji XU, Haitang ZHANG, Jiangtao CHI, Qing DONG
  • Publication number: 20180099046
    Abstract: Provided is a humanized antibody and chimeric antibody that specifically binds human sclerostin. The antibodies can be used for treating human bone metabolism related diseases such as osteoporosis (OP).
    Type: Application
    Filed: February 16, 2016
    Publication date: April 12, 2018
    Applicants: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jiajian LIU, Yayuan FU, Haoying ZHANG, Yifang WANG, Zhen ZHANG, Ling ZHANG, Dongbing CUI, Lianshan ZHANG, Weikang TAO
  • Patent number: 9914703
    Abstract: Pyridone derivatives, methods of preparing the pyridone derivatives, and methods of using the pyridone derivatives are provided. In particular, pyridone derivatives of formula (I), and pharmaceutical salts thereof are provided. The pyridone derivatives are useful as mitogen-activated protein kinase kinase (MEK) inhibitors, and can be used as therapeutic agents for treating cancer.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: March 13, 2018
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Wangyang Tu, Haitang Zhang, Guoji Xu, Jiangtao Chi
  • Patent number: 9862765
    Abstract: Provided is an antibody capable of specially recognizing IL-17A and binding to IL-17A. The antibody can be used for treating inflammation and autoimmune diseases caused by elevated expression of interleukin-17A, such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: January 9, 2018
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Lianshan Zhang, Jiajian Liu, Guoqing Cao, Piaoyang Sun
  • Patent number: 9637484
    Abstract: Cycloalkyl acid derivatives, a preparation method thereof, and a pharmaceutical application thereof are described. In particular, a cycloalkyl acid derivative represented by general formula (I) and a medical salt thereof, a preparation method thereof, and an application of the cycloalkyl acid derivative and the medical salt thereof as URAT1 inhibitors, and particularly as therapeutic agents for diseases related to an abnormal uric acid level are described, wherein definitions of substituent groups in general formula (I) are the same as the definitions in the specification.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: May 2, 2017
    Assignees: SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD., JIANGSU HENGRUI MEDICINE CO., LTD.
    Inventors: Jianbiao Peng, Piaoyang Sun, Jiong Lan, Chunyan Gu, Xiaotao Li, Bonian Liu, Chunzhou Han, Qiyue Hu, Fangfang Jin, Qing Dong, Guoqing Cao
  • Patent number: 9586947
    Abstract: New imidazoline derivatives represented by formula (I): preparation methods thereof, pharmaceutical compositions comprising such derivatives, and applications of such derivatives in preparing androgen receptor antagonists and medicaments for treating diseases such as prostate cancer are described.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: March 7, 2017
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Hejun Lu, Piaoyang Sun, Hongbo Fei, Hongjian Jiang, Haowei Wang, Qing Dong
  • Publication number: 20170037044
    Abstract: Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof are provided. Specifically, amide derivatives represented by general formula (I) are provided. The amide derivatives represented by general formula (I) can be used as a therapeutic agent, particularly as an inhibitor for microsomal prostaglandin E synthase-1 (mPGES-1), and also to treat and/or prevent diseases or illnesses such as inflammation and/or pain etc. The definition of each substituent group in general formula (I) is the same as the definition in the description.
    Type: Application
    Filed: March 31, 2015
    Publication date: February 9, 2017
    Applicants: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Xin LI, Wei HE, Xianbo LIU, Bin WANG, Qiyue HU, Fangfang JIN, Qing DONG, Piaoyang SUN
  • Publication number: 20170002090
    Abstract: Ligand-cytotoxic drug conjugates, pharmaceutical compositions, preparation methods, and pharmaceutical uses thereof are provided. More specifically, a ligand-cytotoxic drug conjugate of general formula Pc-(X-Y-D)n is provided. The ligand-cytotoxic drug conjugate can be used to treat cancer via receptor modulation.
    Type: Application
    Filed: January 22, 2015
    Publication date: January 5, 2017
    Applicants: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yali WANG, Lianshan ZHANG, Jindong LIANG, Ang LI, Fanglong YANG
  • Publication number: 20160376367
    Abstract: The present invention provides a human PD-1 antibody, an antigen-binding fragment thereof, and medical use thereof, and further provides a chimeric antibody and humanized antibodies comprising a complementarity-determining region (CDR) of the antibody, a pharmaceutical composition comprising the human PD-1 antibody and the antigen-binding fragment thereof, and use of the antibody in preparing medicines for treating diseases or disorders.
    Type: Application
    Filed: November 14, 2014
    Publication date: December 29, 2016
    Applicant: Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jijun Yuan, Xiangdong Qu, Jufang Lin, Xin Ye, Guoqing Cao, Weikang Tao, Lianshan Zhang, Lei Zhang, Li Yang
  • Patent number: 9527851
    Abstract: The present invention relates to a pyrrole six-membered heteroaryl ring derivative, the preparation method therefor, and the medicinal uses thereof. Specifically, the present invention relates to a new pyrrole six-membered heteroaryl ring derivative as represented by formula (I), the preparation method therefor, a medicinal composition comprising the derivative, and a therapeutic method using same, and, in particular, the uses as a JAK inhibitor and an immunosuppressor. Substituents in formula (I) have the same definitions as in the description.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: December 27, 2016
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xuejun Zhang, Qing Dong, Bonian Liu, Yaoping Zhu, Xiaotao Li, Jiong Lan
  • Publication number: 20160289321
    Abstract: Provided is an antibody capable of specially recognizing IL-17A and binding to IL-17A. The antibody can be used for treating inflammation and autoimmune diseases caused by elevated expression of interleukin-17A, such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis.
    Type: Application
    Filed: October 27, 2014
    Publication date: October 6, 2016
    Applicants: SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD., JIANGSU HENGRUI MEDICINE CO., LTD.
    Inventors: Lianshan ZHANG, Jiajian LIU, Guoqing CAO, Piaoyang SUN